Psychedelic plants and fungi have been used in indigenous healing for millennia. Modern research began with Albert Hofmann's synthesis of LSD-25 in 1938, and his accidental self-ingestion in 1943. After scientific and cultural exploration in the 1950s and 1960s, research was nearly halted by government restrictions in the 1970s and 1980s, despite evidence of limited medical risks and therapeutic potential. Today, rigorous studies are abundant, including clinical trials with MDMA-assisted therapy for PTSD, alcoholism, and social anxiety, psilocybin studies for depression and addiction, investigations into psychedelics' ability to catalyze spiritual experiences and inspire creativity, and neuroscientific research on their nervous system effects.
This work reviews evidence on whether MDMA (ecstasy) causes neurotoxicity in humans. The authors examine clinical and observational studies assessing the drug's effects on the brain's serotonin system. They conclude that MDMA use is associated with lasting changes in serotonergic function, including reduced serotonin transporter density and altered neurotransmitter activity, suggesting potential neurotoxic effects. However, the review notes limitations in human studies, such as confounding factors and lack of definitive causal evidence. The findings indicate that while MDMA can produce neurobiological alterations, the extent and clinical significance of neurotoxicity remain uncertain.